Short-interval variability and test-retest reliability of Alzheimer’s disease plasma biomarkers in a clinically heterogenous cohort
BACKGROUND: Assessment of short-term within-subject variability and test-retest reliability of Alzheimer's disease (AD)-related plasma biomarkers is important for real-world clinical implementation and interpretation in research studies. In this study we aimed to assess short-term variability and reliability of core AD plasma biomarkers, proposed ratios, and evaluate a broader proteomic panel. METHODS: Two serial plasma samples were collected from each of the 92 participants enrolled in observational research studies over intervals ranging from 30 minutes to three months. Test-retest reliability and within-subject variability were assessed for 131 biomarkers measured on three immunoassays (Lumipulse G plasma p-tau217; Fujirebio, NULISAseq CNS Disease Panel and NULISAqpcr AD 5-Plex; Alamar Biosciences). We subsequently evaluated the stability of a dual cut-point approach for AD probability diagnostic categorisation and examined whether within-subject variability was associated with inter-sample interval (time between serial blood sampling). RESULTS: All core AD plasma biomarkers assessed in this study (Aβ42, BD-p-tau181, BD-p-tau217, BD-p-tau231, p-tau181, p-tau217, p-tau231, GFAP and NfL) demonstrated strong correlations (r ≥ 0.79) and high reliability (ICC ≥ 0.84). Within-subject variability was moderate to low for core AD plasma biomarkers. Using a validated dual cut-point approach for plasma p-tau217, most individuals (92%) remained within the same diagnostic category (high/indeterminate/low) across both timepoints, and no individual moved across two boundaries (i.e. from high to low AD probability categorisation or vice versa). For the majority of analytes, within-subject variability was not associated with inter-sample interval after adjustment for age and sex, however, the core AD plasma biomarker, NfL did have a significant association. CONCLUSIONS: While core AD plasma biomarkers had limited variability and high reliability over short-intervals, other central nervous system (CNS)-relevant biomarkers showed greater variability, which may be relevant for interpretation in association studies and clinical applications.
Authors
- Henrik Zetterberg
- Melanie Hart (ORCID: https://orcid.org/0000-0002-7396-1916)
- Nick C. Fox (ORCID: https://orcid.org/0000-0002-6660-657X)
- Christopher R S Belder (ORCID: https://orcid.org/0009-0000-0472-870X)
- Ashvini Keshavan (ORCID: https://orcid.org/0000-0003-1043-5721)
- Jonathan M. Schott (ORCID: https://orcid.org/0000-0003-2059-024X)
- Owen Swann (ORCID: https://orcid.org/0000-0002-1464-0274)
- Michael Peter Lunn (ORCID: https://orcid.org/0000-0003-3174-6027)
- Amanda Heslegrave (ORCID: https://orcid.org/0000-0002-7290-6405)
- Miguel Rosa‐Grilo
- Katharine Wiltshire (ORCID: https://orcid.org/0009-0006-0576-7819)
- Millie Beament
- Emily Abel
Institutions
- Royal Adelaide Hospital (AU)
- University of Wisconsin–Madison (US)
- Sahlgrenska University Hospital (SE)
- Queen Elizabeth Hospital (AU)
- UK Dementia Research Institute (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Adelaide University (AU)
- UCL Queen Square Institute of Neurology (GB)
- University College London (GB)
- The University of Adelaide (AU)
- Indian Institute of Science Bangalore (IN)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2026-10-27
- DOI
- https://doi.org/10.1186/s13195-026-02180-8
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hospital Research Foundation
- Alzheimer's Society
- National Institute for Health and Care Research
- British Heart Foundation
- University College London
- Rosetrees Trust
- University College London Hospitals NHS Foundation Trust
- UK Dementia Research Institute
- Medical Research Council
- National Health and Medical Research Council
- UCLH Biomedical Research Centre